ARCT
Arcturus Therapeutics Holdings Inc.·Healthcare
8.36
1.703%(+0.14)
Market ClosedLast Updated: — ET
52W L: $5.8552W H: $24.17
ARCT NEWS
fool.com
Mar 25
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
Cathie Wood added to her stakes in Circle Internet Group, Arcturus Therapeutics, and 10x Genomics on Tuesday. Circle tumbled on Tuesday following reports that regulatory tightening may be on the way for its stablecoin domain.
defenseworld.net
Mar 25
Arcturus Therapeutics Refocuses on Rare Disease mRNA Pipeline After COVID Vaccine Success at ROTH Conf
Arcturus Therapeutics (NASDAQ: ARCT) CEO Joe Payne told investors at the 38th Annual ROTH Conference that the company is refocusing on rare disease programs after gaining approvals for its COVID-19 vaccine in more than 30 countries. Payne said Arcturus had initiated a rare disease strategy for messenger RNA (mRNA) medicines before the pandemic and is now
fool.com
Mar 23
These Are the Only 3 Stocks That Cathie Wood Bought Last Week
Cathie Wood added to her stakes in Figma, Arcturus Therapeutics, and 10x Genomics last week. Analysts see Figma's growth slowing dramatically in the next two years, but an 83% drop from last year's high makes it a compelling consideration.
defenseworld.net
Mar 23
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $29.50 Average Target Price from Brokerages
Arcturus Therapeutics Holdings Inc. (NASDAQ: ARCT - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen research firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one
defenseworld.net
Mar 12
Arcturus Therapeutics Teases 12-Week Phase 2 CF Study After Well-Tolerated Inhaled mRNA Dosing
Arcturus Therapeutics (NASDAQ: ARCT) Chief Executive Officer Joe Payne told investors at the Leerink Partners Global Healthcare Conference that the company has advanced its inhaled messenger RNA cystic fibrosis (CF) program through three Phase 2 cohorts and is preparing to initiate a longer 12-week study designed to better evaluate lung function outcomes. CF program: 28-day cohorts
businesswire.com
Mar 5
Arcturus Therapeutics to Attend Upcoming Investor Conference
SAN DIEGO--(BUSINESS WIRE)---- $ARCT #ClinicalTrial--Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a messenger RNA medicines company focused on the development of liver and respiratory rare disease therapeutics, today announced that the Company will participate in the following investor conference, in Miami, Florida: Leerink Partners 2026 Global Healthcare Conference (Fireside Chat) Wednesday, March 11, 2026 (11:20 a.m. ET) Webcast link can be found under Investor Relations/Events secti.
